{"groups":[{"description":"Patients receive erdafitinib 8 mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout study. Patients may also undergo blood sample collection and tumor biopsy throughout the trial.","id":"FG000","title":"Treatment (Erdafitinib)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"17"}],"type":"Mutation Status Not Confirmed"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Physician Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"Started Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"comment":"Primary efficacy analysis population","type":"Eligible, Treated and Mutation Status Confirmed"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Treatment continued until disease progression or intolerability","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The FGFR amplification status was determined by assay performed in a NCI-MATCH approved laboratory for all patients in this arm. Mutation status was confirmed by central MATCH assay for 18 patients.","recruitmentDetails":"The study was activated on June 20, 2018. Thirty-five patients were enrolled between August 20, 2018, and April 30, 2019."}